Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future

References

• Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31:845–53.
   PubMed Web of Science ®Google Scholar
• den Dulk M, Krijnen P, Marijnen CA, Rutten HJ, van de Poll-Franse LV, Putter H, Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-operative radiotherapy. Eur J Cancer. 2008;44:1710–16.
   PubMed Web of Science ®Google Scholar
• Lemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975–2007: rectal cancer survival levels with colon cancer survival. Acta Oncol. 2010;49:784–96.
   PubMed Web of Science ®Google Scholar
• Klint A, Engholm G, Storm HH, Tryggvadottir L, Gislum M, Hakulinen T, Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:578–607.
   PubMed Web of Science ®Google Scholar
• Stahle E, Enblad P, Pahlman L, Glimelius B. Can mortality from rectal and rectosigmoid carcinoma be predicted from histopathological variables in the diagnostic biopsy? APMIS. 1989;97:513–22.
   PubMed Web of Science ®Google Scholar
• Bratland A, Vetrhus T, Groholt KK, Ree AH. Preoperative radiotherapy in rectal signet-ring cell carcinoma—magnetic resonance imaging and treatment outcome: Report of six cases. Acta Oncol. 2010;49:42–9.
   PubMed Web of Science ®Google Scholar
• Sundstrom M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer. 2010;10:660.
   PubMed Web of Science ®Google Scholar
• Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Multidisciplinary rectal cancer management. Radiother Oncol. 2009;92:148–63.
   PubMed Web of Science ®Google Scholar
• Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology. 2004;232:773–83.
   PubMed Web of Science ®Google Scholar
• Smith N, Brown G. Preoperative staging in rectal cancer. Acta Oncol. 2008;47:20–31.
   PubMed Web of Science ®Google Scholar
• Quirke P, Cuvelier C, Ensari A, Glimelius B, Laurberg S, Ortiz H, Evidence-based medicine: the time has come to set standards for staging. J Pathol. 2010;221:357–60.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Pahlman L, Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 2011;29:2142–3.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer—a systematic overview. Rev Recent Clin Trials. 2008;3:204–11.
   PubMedGoogle Scholar
• Valentini V, Glimelius B. Rectal cancer radiotherapy: Towards European consensus. Acta Oncol. 2010;49:1206–16.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.
   PubMed Web of Science ®Google Scholar
• NCI. Clinical announcement. Adjuvant therapy of rectal cancer, March 14. Bethesda, Maryland, US: National Cancer Institute; 1991.
   Google Scholar
• Glimelius B. Chemoradiotherapy for rectal cancer—is there an optimal combination? Ann Oncol. 2001;12:1039–45.
   PubMed Web of Science ®Google Scholar
• Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7.
   PubMed Web of Science ®Google Scholar
• Påhlman L, Glimelius B, Graffman S. Pre- versus postoperative radiotherapy in rectal carcinoma: an interim report from a randomized multicentre trial. Br J Surg. 1985;72:961–6.
   PubMed Web of Science ®Google Scholar
• Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal carcinoma: a report from a randomized multicenter trial. Ann Surg. 1990;211:187–95.
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
   PubMed Web of Science ®Google Scholar
• Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favouring preoperative treatment. Int J Radiat Oncol Biol Phys. 1997;37:281–7.
   PubMed Web of Science ®Google Scholar
• Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, Long-term results of a randomised trial comparing preoperative short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.
   PubMed Web of Science ®Google Scholar
• Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). Proc Am Soc Clin Oncol, J Clin Oncol. 2010;28 (suppl), abstr 3509.
   Web of Science ®Google Scholar
• Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer—a systematic overview. Acta Oncol. 2007;46:504–16.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Påhlman L, A randomized phase III study (LARCS) comparing preoperative radiotherapy alone versus chemoradiotherapy in non-resectable rectal cancer. J Clin Oncol. 2008;26:3687–94.
   PubMed Web of Science ®Google Scholar
• Bujko K, Kepka L, Michalski W, Nowacki MP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol. 2006;80:4–12.
   PubMed Web of Science ®Google Scholar
• Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjodahl R, The Swedish rectal cancer registry. Br J Surg. 2007;94:1285–92.
   PubMed Web of Science ®Google Scholar
• Wibe A, Moller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002;45:857–66.
   PubMed Web of Science ®Google Scholar
• Doornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of transanal endoscopic microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol. 2009;48:343–53.
   PubMed Web of Science ®Google Scholar
• Baatrup G, Endreseth BH, Isaksen V, Kjellmo A, Tveit KM, Nesbakken A. Preoperative staging and treatment options in T1 rectal adenocarcinoma. Acta Oncol. 2009;48:328–42.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Ortholan C, Benezery K, Ginot A, Hannoun-Levi JM, Chamorey E, Contact X-ray therapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice, 2002–2006. Int J Radiat Oncol Biol Phys. 2008;72:665–70.
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Preoperative radiotherapy in combination with total mesorectal excision improves local control in resectable rectal cancer. Report from a multicenter randomized trial. New Engl J Med. 2001;345:638–46.
   PubMed Web of Science ®Google Scholar
• Folkesson J, Birgisson H, Påhlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.
   PubMed Web of Science ®Google Scholar
• Radu C, Berglund Å, Påhlman L, Glimelius B. Short course preoperative radiotherapy with delayed surgery in rectal cancer—a retrospective study. Radiother Oncol. 2008;87:343–9.
   PubMed Web of Science ®Google Scholar
• Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92:210–14.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.
   PubMed Web of Science ®Google Scholar
• Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Strobel P, Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74:1487–93.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer—is the water getting muddy? Acta Oncol. 2010;49:278–86.
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol. 2011;22:2424–30.
   PubMed Web of Science ®Google Scholar
• Resch G, De Vries A, Ofner D, Eisterer W, Rabl H, Jagoditsch M, Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer—A two stage phase II clinical trial. Radiother Oncol. 2012;102:10–13.
   PubMed Web of Science ®Google Scholar
• Nogue M, Salud A, Vicente P, Arrivi A, Roca JM, Losa F, Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614–20.
   PubMed Web of Science ®Google Scholar
• Dewdney A, Capdevila J, Glimelius B, Cervantes A, Tait DM, Brown G, EXPERT-C: a randomized phase II European multicenter trial of neoadjuvant chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. Proc Am Soc Clin Oncol; J Clin Oncol. 2011;29(Suppl):abstr 3513.
   Google Scholar
• Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–17.
   PubMed Web of Science ®Google Scholar
• Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25:1014–20.
   PubMed Web of Science ®Google Scholar
• Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol. 2010;49:378–81.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Mawdsley S, Pearce T, Buyse M. Alternative clinical end points in rectal cancer—are we getting closer? Ann Oncol. 2006;17:1239–48.
   PubMed Web of Science ®Google Scholar
• Bujko K, Kolodziejczyk M, Nasierowska-Guttmejer A, Michalski W, Kepka L, Chmielik E, Tumour regression grading in patients with residual rectal cancer after preoperative chemoradiation. Radiother Oncol. 2010;95:298–302.
   PubMed Web of Science ®Google Scholar
• Barbaro B, Fiorucci C, Tebala C, Valentini V, Gambacorta MA, Vecchio FM, Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology. 2009;250:730–9.
   PubMed Web of Science ®Google Scholar
• Calvo FA, Domper M, Matute R, Martinez-Lazaro R, Arranz JA, Desco M, 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58:528–35.
   PubMed Web of Science ®Google Scholar
• Lambrecht M, Deroose C, Roels S, Vandecaveye V, Penninckx F, Sagaert X, The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol. 2010;49:956–63.
   PubMed Web of Science ®Google Scholar
• Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C, Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22:650–6.
   PubMed Web of Science ®Google Scholar
• Yoon MS, Ahn SJ, Nah BS, Chung WK, Song JY, Jeong JU, The metabolic response using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer. Radiother Oncol. 2011;98:134–8.
   PubMed Web of Science ®Google Scholar
• Avoranta ST, Korkeila EA, Minn HR, Syrjänen KJ, Pyrhönen SO, Securin indentifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy. Acta Oncol. 2011;50:1158–66.
   PubMed Web of Science ®Google Scholar
• Quirke P, Morris E. Reporting colorectal cancer. Histopathology. 2007;50:103–12.
   PubMed Web of Science ®Google Scholar
• Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radio(chemo)therapy? A systematic review of randomized trials. Ann Oncol. 2010;21:1743–50.
   PubMed Web of Science ®Google Scholar
• Glimelius B. Adjuvant chemotherapy in rectal cancer—an issue or a non-issue? Ann Oncol. 2010;21:1739–41.
   PubMed Web of Science ®Google Scholar
• Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? J Clin Oncol. 2007;25:4379–86.
   PubMed Web of Science ®Google Scholar
• Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1129–42.
   PubMed Web of Science ®Google Scholar
• Ippolito E, Mertens I, Haustermans K, Gambacorta MA, Pasini D, Valentini V. IGRT in rectal cancer. Acta Oncol. 2008;47:1317–24.
   PubMed Web of Science ®Google Scholar
• Caravatta L, Padula GD, Picardi V, Macchia G, Deodato F, Massaccesi M, Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: Results of a phase II study. Acta Oncol. 2011;50:1151–7.
   PubMed Web of Science ®Google Scholar
• Syk E, Torkzad MR, Blomqvist L, Ljungqvist O, Glimelius B. Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer. Br J Surg. 2006;93:113–19.
   PubMed Web of Science ®Google Scholar
• Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B. Local recurrence in rectal cancer: Anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys. 2008;72:658–64.
   PubMed Web of Science ®Google Scholar
• Nijkamp J, Kusters M, Beets-Tan RG, Martijn H, Beets GL, van de Velde CJ, Three-dimensional analysis of recurrence patterns in rectal cancer: The cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys. 2011;80:103–10.
   PubMed Web of Science ®Google Scholar
• Kusters M, Wallner C, Lange MM, Deruiter MC, van de Velde CJ, Moriya Y, Origin of presacral local recurrence after rectal cancer treatment. Br J Surg. 2010;97:1582–7.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhou ZG, Yu YY, Li Y, Lei WZ, Cheng Z, Patterns of lateral pelvic lymph node metastases and micrometastases for patients with lower rectal cancer. Eur J Surg Oncol. 2007;33:463–7.
   PubMed Web of Science ®Google Scholar
• Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg. 2008;95:33–49.
   PubMed Web of Science ®Google Scholar
• Taylor N, Crane C, Skibber J, Feig B, Ellis L, Vauthey JN, Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. Int J Radiat Oncol Biol Phys. 2001;51:741–7.
   PubMed Web of Science ®Google Scholar
• West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol. 2008;26:3517–22.
   PubMed Web of Science ®Google Scholar
• Bakx R, Emous M, Legemate DA, Zoetmulder FA, van Tienhoven G, Bemelman WA, Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol. 2006;32:520–6.
   PubMed Web of Science ®Google Scholar
• Grau C, Muren LP, Hoyer M, Lindegaard J, Overgaard J. Image-guided adaptive radiotherapy—integration of biology and technology to improve clinical outcome. Acta Oncol. 2008;47:1182–5.
   PubMed Web of Science ®Google Scholar
• Nystrom H, Blomqvist E, Hoyer M, Montelius A, Muren LP, Nilsson P, Particle therapy—a next logical step in the improvement of radiotherapy. Acta Oncol. 2011;50:741–4.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Puyraveau M, Mineur L, Calais G, Bardet E, Maingon P, EORTC 22921 Rectal Cancer Trial: Quality of life (QoL) and functional outcome 5 years after treatment. Eur J Cancer. 2011;abstr 6018.
   Google Scholar
• Braendengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized phase III study. Int J Radiat Oncol Biol Phys. 2011;81:1017–24.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund K, Brandberg Y, Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study. Eur J Cancer. 2011;Jul20 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Glimelius B, Isacsson U. Preoperative radiotherapy for rectal cancer—is 5 x 5 Gy a good or a bad schedule? Acta Oncol. 2001;40:958–67.
   PubMed Web of Science ®Google Scholar